House committee investigates Wyeth's marketing of Rapamune

06/13/2010 | Wall Street Journal, The

The House Oversight and Government Reform Committee is investigating whether Wyeth illegally promoted its drug Rapamune for unapproved use, including for the prevention of organ rejection after heart, liver, pancreas and islet cell transplants. FDA approval for the product is limited to preventing organ rejection after a kidney transplant.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL